WuXi Biologics prices HK IPO top of range as investors jostle for a piece

WuXi Biologics (Cayman) Inc priced its Hong Kong IPO at the top of expectations on Tuesday, raising $511 million in the largest new listing in the Asian financial hub in 2017, as investors jostled for a piece of the fast-growing business.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at subs@dealstreetasia.com.